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Abstract: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide. Developments in the understanding of COPD have led to standard guide-
lines for diagnosis, treatment, and spirometry assessments, which have in turn influenced trial 
designs and inclusion criteria. Substantial clinical evidence has been gained from clinical trials 
and supports a positive approach to COPD management. However, there appear to be changing 
trends in recent trials. Large bronchodilator studies have reported lower improvements in trough 
forced expiratory volume in 1 second (FEV1) values versus placebo than were observed in 
earlier studies, while the rate of FEV1 decline seems to be lower in more recent trials. In addition, 
recent evidence has called into question the usefulness of bronchodilator reversibility testing 
as a trial inclusion criterion. Baseline patient populations and use of concomitant medications 
have also changed over recent years due to increased treatment options. The impact of these 
many variables on clinical trial results is explored, with a particular focus on changes in inclu-
sion criteria and patient baseline demographics.
Keywords: chronic obstructive pulmonary disease, clinical trials, forced expiratory volume in 
1 second, long-acting bronchodilators, lung function
Introduction
Chronic obstructive pulmonary disease (COPD) is a major public health concern and 
is currently the fourth leading cause of death in the United States.1 COPD is a smoking-
related lung disease that progresses over several years with increasing respiratory 
symptoms (eg, dyspnea, coughing, and sputum production) and systemic effects 
(eg, weight loss, skeletal muscle dysfunction, and increased risk of cardiovascular 
disease).1
In previous decades, treatment options for COPD were limited. However, the past 
10–15 years have seen a large increase in clinical trials examining different treatments 
for this disease and substantial developments in COPD management, for example, 
long-acting β2-agonists, long-acting muscarinic antagonists, and their combination 
with inhaled corticosteroids (ICS). Bronchodilators are the mainstay of pharmacologic 
treatment of COPD, and the most widely used are β2-agonists (eg, salbutamol, terb-
utaline, formoterol, and salmeterol), anticholinergics (eg, ipratropium and tiotropium), 
and methylxanthines (eg, theophylline). Bronchodilators in combination with each 
other and with ICS have also been investigated.
Understanding of the clinical phenotypes of COPD is evolving, and there is increas-
ing clinical evidence to guide COPD management. However, several unanswered ques-
tions remain due to the variability in clinical trial procedures and patient populations. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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This review of trials of long-acting bronchodilators examines 
trends observed in recent COPD trials and explores the fac-
tors that may have impacted on the results, with a particular 
focus on changes in patients’ lung function over time.
Literature analysis
A PubMed literature search (restricted to English literature; 
no date restriction) using the terms COPD (MeSH) and 
salmeterol or formoterol or tiotropium was carried out on 
May 14, 2009, and yielded 223 articles (search limits were: 
clinical trial, meta-analysis, randomized controlled trial, and 
humans). To minimize problems due to small sample sizes 
or short study durations, only full articles reporting random-
ized, placebo-controlled clinical trials of at least 500 patients 
and duration of at least 6 months were selected (18 articles) 
for detailed assessment.
Recent trends in bronchodilator 
clinical trial results
Forced expiratory volume in 1 second (FEV1) is the principal 
measure of lung function used in the assessment of COPD. 
A minimum clinically important difference (MCID) has not 
been defined, although improvement of about 100–120 mL 
in trough FEV1 has been suggested as a possible benchmark 
for bronchodilators and anti-inflammatory agents, but this is 
not based on quantitative data.2,3 Regulators may consider a 
change in FEV1 of 5%–10% from baseline values to be 
  clinically meaningful, and that a ,3% change from baseline 
is not clinically important.3 Assuming a baseline FEV1 of 
1.1 L, this would equate to an increase of 55–110 mL, and 
not ,33 mL. Further consideration of a clinically meaningful 
change is needed, particularly since recent results from large 
clinical studies evaluating a range of bronchodilators have 
reported lower improvements in trough FEV1 values for 
monotherapies than those reported in earlier studies.
For example, several studies have reported results of the 
long-acting anticholinergic, tiotropium. The recent 4-year 
Understanding Potential Long-term Impacts on Function 
with Tiotropium (UPLIFT) trial (N = 5992) investigated 
tiotropium versus placebo in patients with COPD, 
and throughout the study, trough FEV1 was significantly 
improved versus placebo by 87–103 mL (Table 1).4 This 
contrasts with a number of previous studies that reported 
improvements in trough FEV1 values with tiotropium over 
placebo that ranged from 100 to 150 mL (Table 1 and 
Figure 1).5–11
The long-acting β2-agonist, salmeterol, has demonstrated 
varying improvements in trough FEV1 compared with   placebo 
of 59–92 mL (Table 1).6,7,12–14 A recent study of another long-
acting β2-agonist, formoterol, showed improved trough FEV1 
compared with placebo (40 mL), but most of the formoterol 
studies were not powered on trough FEV1 (Table 1).15 Since 
our literature search was carried out, a large, 12-month, ran-
domized, double-blind study of 1964 patients has been 
reported, in which budesonide/formoterol demonstrated 
improvements in trough FEV1 compared with placebo 
(∼100–110 mL; P , 0.001).16 Salmeterol in combination 
with the ICS, fluticasone, has demonstrated improvements 
in trough FEV1 compared with placebo ranging from 132 to 
161 mL,12–14 and the combination of formoterol and budes-
onide improved trough FEV1 compared with placebo by a 
range of 50–80 mL (Table 1).15 Short-acting β2-agonists 
(eg, salbutamol) and anticholinergics (eg, ipratropium) have 
a 4–6 h duration of action and, therefore, have a lower effect 
on trough FEV1 compared with longer-acting agents and were 
not included in the literature search.17
A new long-acting antimuscarinic agent, aclidinium 
bromide, is also under development and two large, 12-month, 
randomized, double-blind studies of 1647 patients in total 
have been reported since our literature search was car-
ried out.18,19 When given once daily, 200 µg inhaled acli-
dinium bromide demonstrated improvements in trough FEV1 
compared with placebo of 59–67 mL (P , 0.001) at week 28.
Variable results in peak (ie, postdose) FEV1 have also 
been observed for individual agents across different trials 
(Table 1). Peak FEV1 compared with placebo ranged from 
28 to 191 mL6,12–14,20,21 for salmeterol monotherapy, 
76–231 mL6,12–14,20 for salmeterol + fluticasone, 92–140 mL15,22 
for formoterol, 160–170 mL15 for formoterol + budesonide, 
and 47–244 mL for tiotropium.4–6,8,23
There are no immediately identifiable reasons for the 
differences in measured effect size for the same agent in 
different studies. It may simply be due to random sampling 
from the worldwide population of COPD patients; however, 
it may be useful to explore other possible mechanisms, which 
are evaluated in this review.
Observed changes to COPD clinical 
trial procedures, inclusion criteria, 
and baseline demographics
Guidelines for COPD diagnosis  
and definition
Concerted efforts to define COPD have led to the develop-
ment of guidelines for diagnosis, such as the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) and   International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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American Thoracic Society (ATS)/European Respiratory 
Society (ERS) guidelines, which define COPD as a prevent-
able and treatable disease characterized by airflow limitation 
that is not fully reversible.1,24 Compared with older 
definitions,25,26 this represents a paradigm shift toward positive 
thinking in COPD management. Changes in the understanding 
of the disease and evolving guidelines for its management 
will impact on clinical trial designs and procedures, and trial 
results, in turn, influence clinical guidelines.
Lung function assessments
Alongside guidelines for the diagnosis of COPD, the standard-
ization of spirometry has also improved over recent years. 
Current spirometry guidelines were issued by the ATS/ERS in 
2005,27 which updated previous guidelines published in 1995 
and 1987.28,29 Recommendations specify acceptability and 
reproducibility criteria for forced vital capacity (FVC) and FEV1 
assessments. A minimum of three acceptable assessments should 
have repeatability within 150 mL (or within 100 mL for those 
with an FVC #1.0 L),27 which has shifted from the more lenient 
1995 criteria of repeatability within 200 mL.28 Once these criteria 
are met, ATS/ERS guidelines state that the largest FVC and 
FEV1 values should be selected,27 and although these are widely 
used, others recommend using mean values, such as the mean 
of the best three of five acceptable assessments.2
Spirometric tests performed in different clinics are often 
subject to variability due to technical and personal factors 
such as differences in the use and validation of equipment, 
as well as differences in measurement procedures, interpreta-
tion, and quality control.2,27 To help overcome such limita-
tions, large trials such as UPLIFT have used centralized 
quality assurance of spirometry data.
effect of clinical trial on patient  
baseline demographics
COPD is a heterogeneous disease, and differences in the 
patient inclusion criteria can substantially affect trial results 
and their translation into clinical practice guidelines.
Disease staging of COPD has been classified based on 
spirometry,1,24 and the relative proportions of patients with 
moderate, severe, and very severe COPD within trials may 
have an impact on results. For example, trough FEV1, the 
usual primary outcome measure in trials of long-term bron-
chodilators, is lower in patients with more severe disease and 
thus the magnitude of improvement in such patients would 
be expected to be lower.30 This has been shown in two studies 
of fluticasone propionate/salmeterol (250/25 µg) in different 
patient populations. In a study of patients with COPD who 
had a mean baseline FEV1 of 42% predicted, fluticasone 
propionate/salmeterol increased trough FEV1 by 165 mL 
from baseline to end point,14 whereas in a second study of 
patients with more severe COPD (mean baseline FEV1 of 
33% predicted), fluticasone propionate/salmeterol decreased 
trough FEV1 by 12 mL from baseline to end point.31 Subgroup 
analyses from the Towards a Revolution in COPD Health 
(TORCH) and UPLIFT trials have demonstrated improve-
ments in lung function outcomes in patients with moderate 
(GOLD stage II) COPD.32,33 The TORCH analysis demon-
strated improvements across different subgroups of GOLD 
stages, although lung function improvements decreased with 
increasing disease severity.33 Similar results have been 
observed in a subanalysis of the TRial of Inhaled STeroids 
ANd long-acting β2 agonists (TRISTAN) study.34
Smoking is a key factor in COPD development and, until 
recently, smoking cessation was the only intervention that has 
been prospectively shown to slow the rate of lung function 
decline in COPD.35 The proportion of patients who are current 
smokers and patients’ smoking history are, therefore, key 
baseline characteristics to consider. In a comparison of differ-
ent trials, rates of FEV1 decline in different trials appear to be 
related to the proportion of current smokers at baseline 
(Figure 2). Indeed, a range of factors appears to influence FEV1 
decline, including age, gender, and baseline FEV1, and could 
influence the rates observed in different studies.36 In the 
TORCH study, a slower rate of FEV1 decline in absolute mil-
liliters per year was observed with patients $65 years of age, 
with females, and those with a baseline FEV1 ,30% predict-
ed.36 However, when the rate of FEV1 decline was expressed 
as a percentage change per year, this relationship was preserved 
with patients $65 years of age, but not with females and those 
with a baseline FEV1 ,30% predicted. Moreover, a subanalysis 
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of TRISTAN study data reported that the improvements in 
trough FEV1 with salmeterol/  fluticasone versus placebo were 
equivalent in women (by 152 mL; 95% confidence interval 
95, 208) and men (by 127 mL; 95% confidence interval 94, 
159; P = 0.455 for the gender interaction).37 A recent analysis 
of the Framingham Offspring Cohort, which included 
5124 male and female participants, showed that changes in 
lung function from adolescence to old age differ between 
healthy males and females.38 This analysis of the natural his-
tory of chronic airflow obstruction also confirmed the deleteri-
ous effects of smoking, as the rate of decline in FEV1 was 
increased in smokers compared with never-smokers. Quitting 
smoking earlier is better, as participants who quit after the age 
of 40 years showed no significant difference in FEV1 decline 
compared with continuous smokers.
effect of clinical trial dose selection
There has also been a change in the focus of new drug appli-
cations to regulatory agencies, which may have affected 
outcomes of more recent studies compared with older studies. 
For example, the US Food and Drug Administration (FDA) 
routinely aims to identify the dose with the most favorable 
risk–benefit profile due to concerns about safety. This is, in 
part, a consequence of safety concerns about long-acting 
β2-agonists in asthma: while there is a dose-response for FEV1 
efficacy with formoterol, there is an escalating safety concern 
with higher doses.39 Recent pivotal Phase III studies have 
included lower doses along with the Phase IIa-identified dose; 
therefore, lower improvement in trough FEV1 and other end 
points may be seen compared with earlier studies. For 
example, Phase III trials of nebulized arformoterol investi-
gated a 15 µg twice-daily dose, as well as 25 µg twice daily 
and 50 µg daily.40,41 While the changes in trough or predose 
FEV1 were similar with the three doses, the mean percentage 
change in FEV1 AUC (0–12) was 12.7%, 13.9%, and 18.9% with 
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Figure 2 Rate of Fev1 decline in the placebo arm of long-term COPD studies.4,36,55–57
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  Fev1,  forced 
expiratory volume in 1 second.
15 µg twice daily, 25 µg twice daily, and 50 µg daily, 
  respectively, compared with 2.7% with placebo and 9.8% with 
salmeterol. The lowest arformoterol dose (15 µg twice daily) 
was chosen by FDA for license in the US.40
It has also been suggested that the rate of decline in lung 
function could be affected by bias from regression to the mean 
caused by missing data, such as in the TORCH study with 
salmeterol.42 This is due to the fact that no long-term COPD 
trials are designed to have a full intent-to-treat analysis of lung 
function decline. However, it has been argued that lung function 
decline is not influenced by regression to the mean in random-
ized, placebo-controlled trials such as TORCH, since any 
regression to the mean should affect all groups equally.43
Concomitant medications
Another recent key change in COPD trials inclusion criteria 
relates to concomitant medications, which are now in wide-
spread use. In contrast to earlier studies when treatment options 
were limited, patients at baseline will now often already have 
received a variety of short- and long-acting bronchodilators 
and ICS. These will have already provided benefit to the 
patients, and their increased use over recent years will have 
shifted the baseline characteristics of patients entering trials. 
In the TORCH study, 8%–9% and 18%–22% of patients had 
received prior medication with an inhaled long-acting 
β2-agonist and an ICS, respectively, and 27%–29% of patients 
had received a combination of the two.36 In the UPLIFT trial, 
60% and 61% of patients were receiving prior medication with 
an inhaled long-acting β2-agonist and an ICS, respectively.4
In many studies, however, patients are still required to 
stop the therapy they had been receiving during the run-in 
period prior to randomization, particularly if it is a member 
of the same class as the study medication. Withdrawal of 
maintenance treatment for COPD during a washout period 
may have two important effects. First, withdrawal of the 
drug may lead to worsening symptoms – so patients who do 
not meet stability criteria are not randomized to the study 
therapies. This would lead to selective exclusion of patients 
who may respond to the class of agents under test. Second, 
if the patients are randomized and receive placebo, there is 
evidence that those who have been withdrawn from either 
an ICS or a long-acting β2-agonist during the run-in period 
are more likely to have an exacerbation during the trial.44
Concomitant medications are now excluded from use 
during the trial period less frequently than in the past, in part 
because of ethical issues; patients in both study drug and 
placebo arms are now likely to receive one or more   respiratory 
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allowed all respiratory therapeutics, with the exception 
of another inhaled anticholinergic agent, in both the tiotro-
pium and placebo arms.4 During the trial, 72% and 74% of 
patients reported having taken an inhaled long-acting 
β2-agonist and an ICS, respectively, while 46% reported 
taking a fixed combination of the two.4 The study authors 
speculate that the concurrent medical care received during 
the study may have contributed to the generally lower rates 
of FEV1 decline across both the tiotropium and the placebo 
groups (which averaged 30 mL/year before bronchodilation 
and 41 mL after bronchodilation in the two groups). Post hoc 
analysis of a relatively small subgroup of patients in the 
UPLIFT trial who were not receiving maintenance therapy 
at baseline (13.5% of the total population) suggests that there 
may be an influence of concomitant therapy on outcome.45 
Another recent study has shown that there may be very clear 
benefits on FEV1 of adding different classes of agent together 
in COPD, since the addition of budesonide + formoterol to 
tiotropium showed a significant (P , 0.001) increase in pre-
dose (ie, trough FEV1) of 65 mL and postdose (peak) of 
131 mL compared with tiotropium alone.46 It, therefore, 
remains a reasonable and testable hypothesis that there may 
be additive effects of pharmacological therapy on FEV1.
It is clear that prestudy and permitted concomitant thera-
pies may have a significant impact on measured treatment 
effects due to selective recruitment, effects of concomitant 
therapy during the study, and events that occur during the 
trial, such as exacerbations.
Bronchodilator reversibility
Substantial progress in understanding the pathophysiology 
of COPD has been made in recent years. A key concern has 
been the differential diagnosis of COPD from chronic asthma. 
As asthma is associated with variable airway caliber, improve-
ment in lung function (eg, FEV1) after bronchodilator treat-
ment (termed bronchodilator reversibility) was proposed as 
a method of distinguishing between the two diseases. 
  Bronchodilator reversibility for an individual patient is 
  commonly defined as a postbronchodilator increase in 
FEV1 $12% and $200 mL from baseline (ATS24 and GOLD47 
criteria) or as a $9% change in predicted FEV1 (ERS 
criteria48).49 This approach has led to a common perception 
that COPD is irreversible, despite evidence that bronchodilator 
reversibility testing was not sensitive or specific enough to 
differentiate asthma from COPD using spirometry alone.50
Previously, European patients, and some patients in the 
US, were selected for COPD clinical studies based on a lack 
of bronchodilator reversibility by assessing how FEV1 
changed following a single dose of bronchodilator (acute 
changes). Clinical studies then investigated reversibility as 
the primary efficacy end point, in terms of changes in pre-
bronchodilator FEV1 over time (chronic changes). Therefore, 
it is perhaps unsurprising that studies show a small response 
in terms of FEV1 change.51 Inclusion based on a lack of 
bronchodilator reversibility may act as a self-fulfilling proph-
ecy for the trial outcomes.
In two studies that investigated salmeterol and fluticasone 
propionate, each as monotherapy and also in combination, 
patient randomization was stratified by reversibility to albuterol 
and investigative site. The results showed that, in both studies, 
patients with reversibility (.12% predicted FEV1) had a greater 
response to therapy than patients with nonreversibility (with 
,4% predicted FEV1) (Figure 3).13,14 Another recent study in 
patients with reversibility and nonreversibility has shown that 
although both groups showed improved lung function with 
fluticasone propionate/  salmeterol, the response was greater 
with patients with reversibility.52 Patients with a history of 
asthma (including childhood asthma) were excluded, and inclu-
sion criteria required diagnosis of COPD with smoking history 
$10 pack years, significant airway obstruction, and medication 
use indicative of COPD. Thus, the authors concluded that the 
greater responsiveness for patients with reversibility could be 
attributed to greater bronchodilator reversibility of their COPD 
and not asthma. The current evidence suggests that strict inclu-
sion criteria based on bronchodilator reversibility are not neces-
sary for future trials. Instead, patients with asthma could be 
differentiated from those with COPD on the basis of history 
(eg, nonsmoking) and normalization of lung function values.
0
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Figure 3 Response to inhaled corticosteroid (fluticasone propionate) + long-acting 
β2-agonist (salmeterol) in reversible and nonreversible patients in COPD.13,14
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Conclusions
Significant advances in the understanding of COPD and 
increases in available treatment options have been made in 
recent years. Clinical evidence supports a positive approach 
to COPD management, and concerted efforts have produced 
standard guidelines for diagnosis and assessment. These 
guidelines influence clinical trial designs and protocols, the 
results of which feed back into clinical guidelines in a con-
tinuous process. This review of data from recent trials in 
COPD has some unexpected results, for example, the results 
from the recent large UPLIFT trial of tiotropium reported 
lower trough FEV1 outcomes than most previous studies with 
this drug. Current clinical trial results may not be directly 
comparable to earlier studies due to substantial changes in 
the availability of concomitant medications and in the base-
line patient populations over time, including use of prior 
medications, smoking status and history, and disease severity. 
The impact of such factors on trial outcomes should be care-
fully evaluated, and consideration should be given as to 
whether long-acting bronchodilators can achieve a trough 
FEV1 value .60–100 mL in future studies. This will require 
formal study with a full evaluation of indicative values for 
the MCID of trough and peak FEV1 changes.
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